Announcement on the Addition and Activation of the Company Name “Wuxi Hycells Biotechnology Co., Ltd.”
Release Date:
2026-02-10 16:51
Notice on Adjusting the Entity Responsible for Business Acceptance and Activating the New Issuing Entity
To All Partners, Customers, and Relevant Organizations:
To align with the company’s overall strategic development plan, further optimize resource allocation efficiency, and enhance the quality of integrated services and core competitiveness, we hereby issue the following official notice regarding the unified adjustment of the entity responsible for business undertaking and the entity authorized to issue external official documents:
Wuxi Hycells Biotechnology Co., Ltd. is the wholly owned parent company of Shanghai Hycells Biotechnology Co., Ltd.
It will be comprehensively upgraded into the operations, production, and business hub of the Hycells Bio-system, centrally handling external procurement of products, technical services, project collaborations, and various other business partnerships. Following the restructuring, the two companies will collaborate on undertaking and jointly executing relevant business activities while assuming corresponding responsibilities.
This restructuring represents an internal optimization and consolidation of the company’s organizational structure. Wuxi Hycells Biotechnology Co., Ltd. will, in accordance with applicable laws and regulations, fully succeed to all rights, obligations, and legal liabilities of Shanghai Hycells Biotechnology Co., Ltd. within the aforementioned scope of business. All previously executed contracts, agreements, and various commitments shall remain legally valid and enforceable, and we will make every effort to ensure seamless transition and smooth performance of all ongoing collaborations. The company’s core operating team, technical implementation standards, product quality control system, and service philosophy of “customer first, professional and efficient” will all remain unchanged.
This organizational restructuring will enable us to allocate resources more efficiently, focus on our core business, and deliver higher-quality, more comprehensive support and services to our partners and customers. We sincerely apologize for any inconvenience the transition may cause and express our heartfelt gratitude for your understanding, trust, and continued support.
Related News
818 Breakthrough Technology | Integrated Culture Protocol for γδ T Cells
The implementation of the “818 Regulations” marks the official entry of China’s cell therapy industry into a new phase of standardized development, one that prioritizes clinical efficacy as the benchmark for value, upholds rigorous compliance across the entire value chain as an inviolable baseline, and harnesses differentiated technological innovation as the core driver of progress. The Regulations explicitly restrict low-level duplication and homogeneous competition, while giving priority to the translation of technology pathways that demonstrate clear clinical value and outstanding scientific innovation, thereby establishing clear compliance boundaries and a well-defined innovation orientation for the industry’s future development.
Conference Announcement | Hycells cordially invites you to join the 3rd Boao Lecity Stem Cell Summit
From March 20 to 22, 2026, the Third Boao Lecity Stem Cell Conference, co-hosted by the China Anti-Aging Promotion Association and Hainan University, will be held in Boao Lecity, Hainan. With the theme “Cell Therapy Pioneering the Third Medical Revolution,” the conference will also make a major announcement of the latest batch of cell therapy procedures that are now permitted to be billed, thereby establishing an international high-end platform that brings together cutting-edge ideas, translates research into clinical practice, fosters industry collaboration, and jointly develops policies and standards.
A Tribute to the Woman Who Provides “Cell-Level” Protection in the Field of Life Sciences
In the world of biopharmaceuticals, cells are the fundamental units of life; at Hycells Biotechnology, women are the driving force behind global progress. From relentless pursuit in the laboratory to compassionate care on the clinical front lines, women’s sensitivity, resilience, and wisdom—like the “primary cell” technology we have meticulously cultivated—harness the most primal and essential power to propel innovation and shape the future of our field.
Hycells Biotechnology is a biotechnology innovation company specializing in research on primary immune cells and hepatocytes. We are committed to providing customers with comprehensive, one-stop solutions for immune cells and stem cells, leveraging scientific innovation to drive industry development and delivering expert services to empower clinical research.
3.0 High-Efficiency NK Serum-Free Culture Kit | Chapter 1: Cord Blood–Derived CBNK
Hycells Biotechnology’s newly launched 3.0 High-Efficiency Serum-Free NK Cell Culture Kit (Catalog No.: NK888-2L), in collaboration with the CBMC Seed Bank, provides a comprehensive, integrated cell culture solution: from thawing and recovering CBMC seed stocks or directly and efficiently expanding fresh CBMCs, to ultimately obtaining NK cells with high purity and high viability. This integrated culture system supports flexible expansion based on cell status, with a scalable culture volume of up to 10 liters, delivering outstanding culture performance and exceptional cost-effectiveness, and earning widespread trust and recognition from customers.
New Product | Hycells Announces the Launch of High-Viability Primary Hepatocyte Cells!
Within 4 hours after recovery, its cytochrome P450 enzyme activity is most similar to that in vivo, making it suitable for short-term metabolic studies.